Pages that link to "Q36083431"
Jump to navigation
Jump to search
The following pages link to Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions (Q36083431):
Displaying 50 items.
- Uveal melanoma as a target for immune-therapy (Q26747519) (← links)
- Immune escape mechanisms as a guide for cancer immunotherapy (Q27024502) (← links)
- Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site (Q28066935) (← links)
- Cutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system (Q30235983) (← links)
- Immunotherapy as a Potential Treatment for Chordoma: a Review (Q33276143) (← links)
- Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies (Q33576327) (← links)
- Inhibition of STAT3 activity re-activates anti-tumor immunity but fails to restore the immunogenicity of tumor cells in a B-cell lymphoma model (Q34028436) (← links)
- Immunology of naturally transmissible tumours. (Q34041901) (← links)
- Complement anaphylatoxins as immune regulators in cancer (Q34414162) (← links)
- Cancer immunotherapy: Progress and challenges in the clinical setting (Q36184314) (← links)
- HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition (Q36184954) (← links)
- Immunotherapy of cancer in 2012. (Q36243536) (← links)
- Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy (Q36283696) (← links)
- Soluble HLA-G: Are they clinically relevant? (Q36384011) (← links)
- NK cell receptors as tools in cancer immunotherapy. (Q36543814) (← links)
- Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer (Q36664213) (← links)
- The tumor microenvironment and its role in promoting tumor growth (Q36946019) (← links)
- NK cell receptors and their ligands in leukemia (Q37018656) (← links)
- Immune responses to malignancies (Q37040501) (← links)
- Natural killer cell-directed therapies: moving from unexpected results to successful strategies (Q37143139) (← links)
- Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands (Q37242917) (← links)
- HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance (Q37287152) (← links)
- Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma (Q37308192) (← links)
- The biology of interleukin-2 efficacy in the treatment of patients with renal cell carcinoma (Q37369953) (← links)
- Natural killer cell tolerance licensing and other mechanisms. (Q37397516) (← links)
- Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide (Q37414561) (← links)
- Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells (Q37605030) (← links)
- PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma (Q37630808) (← links)
- Improved transplantation outcome by epigenetic changes (Q37752924) (← links)
- The tumor microenvironment: part 1. (Q37952794) (← links)
- Deciphering and reversing tumor immune suppression. (Q38124437) (← links)
- Chondroitin sulfate proteoglycan 4 as a target for chimeric antigen receptor-based T-cell immunotherapy of solid tumors (Q38550541) (← links)
- Intracellular antigens as targets for antibody based immunotherapy of malignant diseases (Q38644355) (← links)
- Epithelial-to-mesenchymal transition (EMT) induced by inflammatory priming elicits mesenchymal stromal cell-like immune-modulatory properties in cancer cells. (Q38911110) (← links)
- Cancer treatment and the KIR-HLA system: an overview. (Q39131056) (← links)
- Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma (Q39190801) (← links)
- Interactions of dendritic cells with cancer cells and modulation of surface molecules affect functional properties of CD8 T cells (Q39532286) (← links)
- Up-regulate HLA class I expression following hepatitis B virus transfection in a hepatocellular carcinoma cell line BEL7405. (Q39676763) (← links)
- How the devil facial tumor disease escapes host immune responses. (Q41995093) (← links)
- HLA-mediated tumor escape mechanisms that may impair immunotherapy clinical outcomes via T-cell activation (Q42702294) (← links)
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer (Q47652834) (← links)
- Prospects of chimeric antigen receptor T cell therapy in ovarian cancer. (Q52322737) (← links)
- Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme. (Q52663432) (← links)
- Targeting sarcoma tumor-initiating cells through differentiation therapy. (Q52877564) (← links)
- Immune and genomic signatures in oral (head and neck) cancer (Q58700648) (← links)
- Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. (Q64889220) (← links)
- Chimeric antigen receptor T cell therapy in pancreatic cancer: from research to practice (Q88574706) (← links)
- How patients with an intact immune system develop head and neck cancer (Q90211056) (← links)
- The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy (Q90452290) (← links)
- Computing Skin Cutaneous Melanoma Outcome From the HLA-Alleles and Clinical Characteristics (Q91790659) (← links)